ACC 2013


Golden Gate Bridge and Fort Point, San Francisco; Credit: David Ball

The American College of Cardiology's 62nd Annual Scientific Session took place March 9-11, 2013, in San Francisco, California.


Thrombolytic improves PE treatment for some

HT Staff Read Article
Published: 03/14/13

CT scan showing pulmonary
embolism; Credit: Medical
College of Georgia

Adding the thrombolytic drug tenecteplase to standard treatment for pulmonary embolism (PE) can prevent hemodynamic collapse in certain patients, a new study has shown. This benefit was accompanied by an increased risk of major bleeding and hemorrhagic stroke. But younger patients were more likely to derive benefit without these risks. Stavros Konstantinides, MD, PhD, of the University of Mainz in Germany, and his colleagues presented these findings at the . . . [Read Article]

New antiplatelet drug seems more effective than standard

HT Staff Read Article
Published: 03/13/13

Credit: Andre E.X. Brown

The novel antiplatelet agent cangrelor is more effective than clopidogrel as thromboprophylaxis for patients undergoing coronary stent procedures, results of the CHAMPION PHOENIX trial suggest. Researchers found that intravenous cangrelor reduced the overall odds of complications from stenting procedures, including death, myocardial infarction, ischemia-driven revascularization, and stent thrombosis. Treatment with cangrelor also resulted in significantly higher rates of major and minor bleeding as compared . . . [Read Article]

ESA found lacking in anemic heart failure patients

HT Staff Read Article
Published: 03/13/13

Injectable drugs

The erythropoietin-stimulating agent darbepoetin alfa does not offer significant benefits to anemic patients with systolic heart failure, according to a new study. Patients who received the drug did experience an increase in hemoglobin levels. But the rates of death and hospitalization for worsening heart failure were similar among patients taking darbepoetin alfa and those taking a placebo. These findings were presented at the 2013 American College of Cardiology Scientific Session . . .  [Read Article]

Older RBCs can impair blood vessel function

HT Staff Read Article
Published: 03/12/13

blood_for_donation_Juan_D_ Alfonso_230.jpg
Blood for transfusion
Credit: Juan D. Alfonso

Transfusing red blood cells (RBCs) that are more than 3 weeks old can result in impaired blood vessel function, according to a study presented at the 2013 American College of Cardiology Scientific Session. Previous studies have suggested that transfusing blood stored for more than a few weeks may have adverse effects in patients undergoing cardiac surgery or critical care. The new study provides a possible explanation: a deficiency in nitric oxide. [Read Article]

Intervention reduces need for transfusions after PCI

HT Staff Read Article
Published: 03/11/13

Blood for transfusion

New research suggests a clinical decision support tool can help physicians identify patients at high risk of bleeding complications after percutaneous coronary intervention (PCI) and guide the use of bleeding avoidance strategies. After identifying high-risk patients using a pre-PCI bleeding-risk score, physicians administered the direct thrombin inhibitor bivalirudin. And this intervention reduced the incidence of overall complications after PCI, the number of . . . [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}